FDA Inspection 1315938 — Boehringer Ingelheim Pharma GmbH & Co. KG
The FDA completed an inspection of Boehringer Ingelheim Pharma GmbH & Co. KG on May 15, 2025 in Ingelheim am Rhein. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 15, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Ingelheim am Rhein (Germany)
Additional Details
Mutual Recognition Agreement (MRA)